5 completed, 3 terminated, 2 active not recruiting, 2 recruiting. 12 Phase 3, 1 Phase 2.
By phase and status
Follow rozanolixizumab: new trials by email Literature Review of rozanolixizumab trials Research Report on rozanolixizumab
Trials (filtered) newest first · largest first
All 12 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis Rozanolixizumab - Ocular Myasthenia Gravis | Phase 3 | Recruiting | 100 | 2026-09-16 | 2026-11-06 |
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis Rozanolixizumab, Placebo - Ocular Myasthenia Gravis | Phase 3 | Recruiting | 120 | 2026-05-27 | 2026-11-06 |
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis rozanolixizumab - Generalized Myasthenia Gravis | Phase 3 | Active not recruiting | 13 | 2024-10-08 | 2026-11-06 |
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis rozanolixizumab - Generalized Myasthenia Gravis | Phase 2 / Phase 3 | Completed | 14 | 2024-06-14 | 2026-10-27 |
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG) Rozanolixizumab - Generalized Myasthenia Gravis | Phase 3 | Completed | 62 | 2023-04-17 | 2025-11-06 |
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD) Rozanolixizumab, Placebo - Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) | Phase 3 | Active not recruiting | 113 | 2022-02-02 | 2026-10-27 |
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis Rozanolixizumab - Generalized Myasthenia Gravis | Phase 3 | Completed | 165 | 2021-02-03 | 2026-08-20 |
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Rozanolixizumab - Primary Immune Thrombocytopenia | Phase 3 | Terminated | 43 | 2021-01-06 | 2024-02-05 |
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Rozanolixizumab, Placebo - Primary Immune Thrombocytopenia | Phase 3 | Terminated | 30 | 2020-06-03 | 2023-08-08 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Rozanolixizumab, Placebo - Primary Immune Thrombocytopenia | Phase 3 | Terminated | 33 | 2020-01-31 | 2025-03-18 |
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Rozanolixizumab - Generalized Myasthenia Gravis | Phase 3 | Completed | 71 | 2019-10-29 | 2026-08-20 |
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Rozanolixizumab, Placebo - Generalized Myasthenia Gravis | Phase 3 | Completed | 200 | 2019-06-03 | 2026-08-20 |
Conditions studied
Myasthenia Gravis (8) · Purpura, Thrombocytopenic, Idiopathic (3) · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (1)
Sponsors
UCB Biopharma SRL (12)
Countries
Poland (12) · Japan (11) · United States (10) · Italy (9) · Spain (9) · France (8) · Germany (8) · Georgia (7) · Russia (6) · Taiwan (6) · United Kingdom (6) · Canada (5) · China (4) · Czechia (4) · Ukraine (4)
Results publications
PMID 37059507, PMID 42388397, PMID 40105996, PMID 33219142, PMID 35674086, PMID 38099334, PMID 38978809, PMID 39297052, PMID 39552477, PMID 40755069, PMID 41074934, PMID 41205003
NIH funding
2019 (5), 2025 (2), 2023 (1)